111 EBITDA 2018-2024 | YI
111 ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
| 111 Annual EBITDA (Millions of US $) |
|
|---|---|
| 2023 | $-46 |
| 2022 | $-48 |
| 2021 | $-96 |
| 2020 | $-70 |
| 2019 | $-69 |
| 2018 | $-57 |
| 2017 | $-36 |
| 111 Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2024-06-30 | $0 |
| 2024-03-31 | $1 |
| 2023-12-31 | $-29 |
| 2023-09-30 | $-11 |
| 2023-06-30 | $-6 |
| 2023-03-31 | $-3 |
| 2022-12-31 | $-14 |
| 2022-09-30 | $-11 |
| 2022-06-30 | $-12 |
| 2022-03-31 | $-16 |
| 2021-12-31 | $-18 |
| 2021-09-30 | $-27 |
| 2021-06-30 | $-29 |
| 2021-03-31 | $-26 |
| 2020-12-31 | $-25 |
| 2020-09-30 | $-18 |
| 2020-06-30 | $-13 |
| 2020-03-31 | $-16 |
| 2019-12-31 | $-24 |
| 2019-09-30 | $-17 |
| 2019-06-30 | $-15 |
| 2019-03-31 | $-16 |
| 2018-09-30 | $-19 |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.052B | $2.105B |
| 111, Inc. operates as a digital and mobile healthcare platform. The Company offers pharmacy distribution, medical consultancy, e-prescription and other services. 111, Inc. is headquartered in Shanghai, China. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $9.226B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $5.656B | 176.38 |
| Hims & Hers Health (HIMS) | United States | $5.534B | 140.72 |
| Enovis (ENOV) | United States | $2.608B | 17.68 |
| Privia Health (PRVA) | United States | $2.587B | 215.60 |
| IRhythm Technologies (IRTC) | United States | $2.316B | 0.00 |
| Azenta (AZTA) | United States | $2.209B | 110.15 |
| Omnicell (OMCL) | United States | $2.116B | 69.23 |
| 10x Genomics (TXG) | United States | $1.732B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.689B | 0.00 |
| Schrodinger (SDGR) | United States | $1.518B | 0.00 |
| Phreesia (PHR) | United States | $1.148B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.690B | 0.00 |
| Standard BioTools (LAB) | United States | $0.596B | 0.00 |
| Talkspace (TALK) | United States | $0.583B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.547B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.505B | 87.40 |
| Health Catalyst (HCAT) | United States | $0.495B | 0.00 |
| Pulmonx (LUNG) | United States | $0.268B | 0.00 |
| TruBridge (TBRG) | United States | $0.247B | 71.91 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.209B | 0.00 |
| American Well (AMWL) | United States | $0.124B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.112B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.076B | 0.00 |
| HeartBeam (BEAT) | United States | $0.074B | 0.00 |
| CareCloud (CCLD) | United States | $0.046B | 0.00 |
| Outset Medical (OM) | United States | $0.044B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.042B | 0.00 |
| Zepp Health (ZEPP) | China | $0.037B | 0.00 |
| Movano (MOVE) | United States | $0.023B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.017B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.013B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.013B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.005B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |